Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Cash from Financing Activities for 7 consecutive years, with $236.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 17.7% to $236.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $238.6 million, a 50.86% decrease, with the full-year FY2025 number at $238.6 million, down 50.86% from a year prior.
  • Cash from Financing Activities was $236.0 million for Q4 2025 at Nurix Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $237.8 million in Q2 2024 to a low of -$135000.0 in Q4 2022.
  • A 5-year average of $49.9 million and a median of $1.5 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 127.0% in 2022, then skyrocketed 2864485.71% in 2024.
  • Nurix Therapeutics' Cash from Financing Activities stood at $500000.0 in 2021, then tumbled by 127.0% to -$135000.0 in 2022, then surged by 105.19% to $7000.0 in 2023, then surged by 2864485.71% to $200.5 million in 2024, then increased by 17.7% to $236.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Cash from Financing Activities are $236.0 million (Q4 2025), $1.2 million (Q3 2025), and $6000.0 (Q2 2025).